3 Biotech Stocks Leading The Cannabis Boom

Although the growing and selling of marijuana remains the sexiest opportunity in the legal medical marijuana industry, we continue to see the most potential on the biotech side of the industry.

Biotech companies focused on medical marijuana possess the greatest upside potential as they work to develop treatments derived from marijuana, which can be used to improve daily life for millions of people throughout the world.

7 Ways CBD is Saving Lives and Changing the World

From Israel to the United States, the number of studies on the medical benefits of cannabis continues to increase and to provide exciting results.

The cannabis plant has over 100 known chemical compounds but the two best known are cannabidiol (CBD) and tetrahydrocannabinol (THC). Although CBD has a much shorter history than THC, recent research studies have significantly increased our understanding of its medical benefits and its popularity continues to grow.

DEA to Legalize Cannabis? Stocks to Buy

2016 has already been a monumental year for the medical cannabis industry as three separate Phase 3 clinical studies focused on products derived from cannabis have yielded positive results. At this time, we may see a watershed event that will profoundly impact the industry.

The DEA and FDA classify cannabis as a Schedule I substance, which places it in the same category as heroin, LSD, ecstasy, and peyote.

Data Disagrees with DEA

Marijuana Rescheduling May Come Sooner Than You Expect!

In a letter to senators, the Drug Enforcement Administration said that they plan to decide whether marijuana should be reclassified under federal law in the first half of 2016.

The letter was sent in response to a letter from Democratic Senator Elizabeth Warren (Massachusetts) and sever other Democratic Senators in 2015. In the letter, the senators urged the government to facilitate research into the medical benefits associated with marijuana.

Merrill Lynch sees POTential in the Cannabis Industry

In early December, the equity research department at Merrill Lynch, a subsidiary of Bank of America (BAC), released a research report that discusses the POTential of the cannabis industry. During the last two years, the use of medical marijuana in the United States has grown significantly. Approximately one million people current use medical marijuana in the United States and we expect this number to double over the next three years.

What to Expect with GW Pharmaceuticals (GWPH) During 2016

GW Pharmaceuticals plc (GWPH) is a pharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform. GWPH commercialized the world's first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States.

Demand for Cannabidiol Continues to Increase

Over the last two years, there have been a number of reports released which discuss the medical benefits of cannabidiol (CBD), which is non-psychoactive cannabinoid found in the cannabis plant. Researchers have identified at least 85 active cannabinoids in cannabis and CBD accounts for up to 40% of the plant's extract. CBD is considered to have a wider scope of medical applications than tetrahydrocannabinol (THC).